Home > Insider Trading > Filing (0001104659-21-095084)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1737953	Replimune Group Inc.	REPL	Biological Products, (No Disgnostic Substances) (2836)	822082553

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1744425	Pamela Esposito	C/O Replimune Group, Inc., 500 Unicorn Park Woburn MA 01801	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-20	4,862	$1.01	215,021	No	4	M	Direct
Common Stock	Disposition	2021-07-20	4,862	$33.05	210,159	No	4	S	Direct
Common Stock	Acquisiton	2021-07-21	12,538	$1.01	222,697	No	4	M	Direct
Common Stock	Disposition	2021-07-21	12,538	$33.17	210,159	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-07-20	4,862	$0.00	4,862	$1.01
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-07-21	12,538	$0.00	12,538	$1.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
63,741		2025-11-01	No	4	M	Direct
51,203		2025-11-01	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 210,159 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 488,102 shares of the Issuer's common stock, 324,649 of which are exercisable as of the date hereof. Due to scrivener's error, footnote 2 of the Form 4 filed on behalf of the reporting person on July 19, 2021 inadvertently overstated the number of options held by the Reporting Person following the transaction reported therein. The amounts stated in this footnote 2 set forth the correct number of options held by the Reporting Person following the transaction reported herein.
The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.